Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: A population-based cohort study

Rheumatology (United Kingdom)

Volumn 54, Issue 7, 2015, Pages 1244-1249

  Chen, Yi Ming ^a,b   Lin, Ching Heng ^a   Lan, Tsuo Hung ^a,b   Chen, Hsin Hua ^a,b   Chang, Shih Ni ^a   Chen, Yi Hsing ^a,b   Wang, Jun Sing ^a,b   Hung, Wei Ting ^a,b   Lan, Joung Liang ^c   Chen, Der Yuan ^a,b,c,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Diabetes; Glucocorticoid; Hydroxychloroquine; Systemic lupus erythematosus

Indexed keywords

GLUCOCORTICOID; HYDROXYCHLOROQUINE; PREDNISOLONE;

ADULT; AGE DISTRIBUTION; ARTICLE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC PATIENT; DOSE RESPONSE; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HAZARD RATIO; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PHARMACEUTICAL CARE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84926344697     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu451     Document Type: Article

References (20)

1. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
2. Bruce IN. 'Not only . . . but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005;44:1492-502.
3. Bruce IN, Urowitz MB, Gladman DD et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159-67.
4. Chung CP, Oeser A, Solus JF et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008;58:2105-12.
5. Solomon DH, Love TJ, Canning C et al. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 2010;69:2114-7.
6. Solomon DH, Massarotti E, Garg R et al. Association between disease-modifying anti-rheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011;305:2525-31.
7. Cansu DU, Korkmaz C. Hypoglycemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology 2008;47:378-9.
8. Gerstein HC, Thorpe KE, Taylor DW et al. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas-a randomized trial. Diabetes Res Clin Pract 2002;55:209-19.
9. Rekedal LR, Massarotti E, Garg R et al. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum 2010;62:3569-73.
10. Penn SK, Kao AH, Schott LL et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2010;37: 1136-42.
11. Wasko MC, Hubert HB, Lingala VB et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007;298:187-93.
12. Hirsch IB, Paauw DS. Diabetes management in special situations. Endocrinol Metab Clin North Am 1997;26: 631-45.
13. Yang L, Tao J, Tang X et al. Prevalence and correlation of conventional and lupus-specific risk factors for cardiovascular disease in Chinese systemic lupus erythematosus patients. J Eur Acad Dermatol Venereol 2012;26: 95-101.
14. Cortes S, Chambers S, Jerónimo A et al. Diabetes mellitus complicating systemic lupus erythematosus-analysis of the UCL lupus cohort and review of the literature. Lupus 2008;17:977-80.
15. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107.
16. Pickup JC, Mattock MB, Chusney GD et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-292.
17. Herder C, Brunner EJ, Rathmann W et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009;32:421-3.
18. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004;49:139-41.
19. Ha Y, Lee KH, Jung S et al. Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. Lupus 2011;20:1027-34.
20. Roberts RO, Bergstralh EJ, Schmidt L et al. Comparison of self-reported and medical record health care utilization measures. J Clin Epidemiol 1996;49:989-95.